On the other hand, the depletion of L-Gln simultaneously with L-Asn, during ALL therapy with the use of L-asparaginase EcAII (carrying L-glutaminase co-activity), increases side effects related to hepatotoxicity, pancreatitis, neurotoxicity, hyperammonemia, hyperglycemia, leukopenia, thrombosis, and bleeding [5,50]. The gene discussed is GLS2; the disease is Hyperammonemia.